American Century Companies Inc. Has $3.40 Million Holdings in Puma Biotechnology, Inc. $PBYI

American Century Companies Inc. raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 21.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1,149,660 shares of the biopharmaceutical company’s stock after purchasing an additional 201,284 shares during the period. American Century Companies Inc. owned approximately 2.32% of Puma Biotechnology worth $3,403,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBYI. Dimensional Fund Advisors LP lifted its holdings in shares of Puma Biotechnology by 24.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company’s stock valued at $2,635,000 after purchasing an additional 170,968 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Puma Biotechnology by 70.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 344,321 shares in the last quarter. Bank of New York Mellon Corp raised its position in Puma Biotechnology by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 340,886 shares of the biopharmaceutical company’s stock valued at $1,009,000 after buying an additional 9,033 shares during the last quarter. Northern Trust Corp lifted its stake in Puma Biotechnology by 2.4% during the 4th quarter. Northern Trust Corp now owns 325,417 shares of the biopharmaceutical company’s stock valued at $993,000 after acquiring an additional 7,678 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Puma Biotechnology by 287.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 222,608 shares of the biopharmaceutical company’s stock valued at $679,000 after acquiring an additional 165,220 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Stock Up 1.4%

PBYI stock opened at $5.04 on Friday. The stock has a market cap of $253.86 million, a P/E ratio of 5.14 and a beta of 1.30. The company has a current ratio of 1.73, a quick ratio of 1.62 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $3.91 and its two-hundred day simple moving average is $3.43. Puma Biotechnology, Inc. has a 1-year low of $2.22 and a 1-year high of $6.07.

Insider Buying and Selling

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 25,592 shares of Puma Biotechnology stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $3.53, for a total value of $90,339.76. Following the sale, the chief executive officer owned 7,202,481 shares of the company’s stock, valued at approximately $25,424,757.93. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jay M. Moyes sold 22,000 shares of the business’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $74,800.00. Following the completion of the transaction, the director owned 53,322 shares in the company, valued at approximately $181,294.80. The trade was a 29.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,649 shares of company stock worth $596,914 in the last ninety days. Corporate insiders own 23.30% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.00.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.